Deals In Depth: April 2014
Celgene penned two major collaborations; Zimmer and Biomet created an orthopedics device giant in their $13.4B merger. Biopharma financing totaled $2.7B in April; and device funding reached $354M, with two IPOs representing 38% of the total.
You may also be interested in...
Jazz Hits High Note With Updated Zanidatamab Data In Biliary Tract Cancer At ASCO
The company said it is in talks with the US FDA for an accelerated approval filing of the HER2-directed bispecific antibody, which showed better ORR and PFS than the standard of care.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.
Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings
More formal meetings are available for in-person sessions with the US FDA. Also, CBER Director Peter Marks offers advice for conducting meetings, from how to do hybrid right to how to include patient groups and foreign regulators.